Should I stay or should I go? If you’ve been singing this 1981 tune by the English punk rock band The Clash to yourself since late September, you are not alone.  In the fourth-quarter selloff last year, U.S. equities lost $4 trillion in combined market value. For those who had chosen to stay and not to go, a sharp market bounce has helped recover much of the losses: after the 17% rally off the December low, the S&P 500 has now returned to early January 2018 levels. For the tech-heavy Nasdaq 100, the decline was deeper, but the bounce was… Read More

Should I stay or should I go? If you’ve been singing this 1981 tune by the English punk rock band The Clash to yourself since late September, you are not alone.  In the fourth-quarter selloff last year, U.S. equities lost $4 trillion in combined market value. For those who had chosen to stay and not to go, a sharp market bounce has helped recover much of the losses: after the 17% rally off the December low, the S&P 500 has now returned to early January 2018 levels. For the tech-heavy Nasdaq 100, the decline was deeper, but the bounce was sharper. At its lowest levels of 2018, the Nasdaq was down 23% from its highs. Since its December lows, though, it has rallied some 19%.  As a result, the Nasdaq is now higher by about 10% from its 2017 levels. —Recommended Link— How I hacked the stock market and got away with thousands. Make $30,000 in 2 months exploiting mispriced stocks like Apple, Starbucks and other quality blue chips. Click here for the easy (and legal) secret… Hardly a record, but still better than money-market returns. It Pays To Hold Fast But stocks are risky, you might… Read More

After a dismal fourth quarter, disheartened investors needed a snap-back rally… and they got it in spades: The S&P 500 rallied 15% from the market’s lows on December 24 through the end of January.  That’s 15% in six weeks. I think it would be fair to say that this is a far better result that many investors had expected. While the rally still wasn’t enough to recover all of 2018’s losses — the S&P 500 now trades just about 2% above its levels of the start of 2018 — this is truly a great showing. January’s rally alone was one… Read More

After a dismal fourth quarter, disheartened investors needed a snap-back rally… and they got it in spades: The S&P 500 rallied 15% from the market’s lows on December 24 through the end of January.  That’s 15% in six weeks. I think it would be fair to say that this is a far better result that many investors had expected. While the rally still wasn’t enough to recover all of 2018’s losses — the S&P 500 now trades just about 2% above its levels of the start of 2018 — this is truly a great showing. January’s rally alone was one for the record books. It was the index’s best single-month performance since October 2015 and the best start of the year since January 1987. But was the snap-back enough to restore investors’ trust in the market? —Recommended Link— URGENT NEWS: Experts Warn Your Pension Is “A Disaster Waiting to Happen” Save your retirement from miserly interest rates and an overstretched stock market with our special “Executive Dividends” Program… Learn more inside.. It should be. In fact, a rational investor shouldn’t have lost faith in the market to begin with. Especially if he or she has a strong-enough plan (like… Read More

Since 1951, the American Cancer Society has been releasing a detailed report on the status of this dreaded disease, and our progress in fighting it.  A valuable feature of these publications is their projections of the number of cancer cases and deaths expected in the country as a whole and in each state, broken down by specific types of cancer. Most recently, for instance, we learned that the recent trend of the decline in mortality rates — a decline that began in 1991 — has continued. As of 2015, the latest year for which figures are available, the mortality rate… Read More

Since 1951, the American Cancer Society has been releasing a detailed report on the status of this dreaded disease, and our progress in fighting it.  A valuable feature of these publications is their projections of the number of cancer cases and deaths expected in the country as a whole and in each state, broken down by specific types of cancer. Most recently, for instance, we learned that the recent trend of the decline in mortality rates — a decline that began in 1991 — has continued. As of 2015, the latest year for which figures are available, the mortality rate dropped to 159 per 100,000 (a decline of 26% since 1991); this translates into 2.3 million-plus fewer cancer deaths over this period. The death rate has declined especially sharply for the four most common cancer types: lung, colorectal, breast, and prostate. This is wonderful news, and there are two big reasons for this progress.  #-ad_banner-#One is related to public-health efforts, in particular the reduction in smoking. In 1991, about 46.3 million adults in the United States (25.7%) smoked cigarettes; by 2016, this number declined to 15.5% of all adults (37.8 million people).  The other has everything to do with science… Read More

If there is a single trait that all game-changing stocks, regardless of their size or industry, share, it would be their outsized growth potential. This comes with the territory. An innovative company can benefit from being a disruptor by grabbing market share from established competition, contributing to the creation of new markets or accelerating the development of existing ones. In every case, if it’s successful, its innovative nature translates into faster-than-average growth. As the company in question grows its profits, its stock price responds in kind, appreciating faster than its peers. An accelerated growth means accelerated share-price appreciation, all else… Read More

If there is a single trait that all game-changing stocks, regardless of their size or industry, share, it would be their outsized growth potential. This comes with the territory. An innovative company can benefit from being a disruptor by grabbing market share from established competition, contributing to the creation of new markets or accelerating the development of existing ones. In every case, if it’s successful, its innovative nature translates into faster-than-average growth. As the company in question grows its profits, its stock price responds in kind, appreciating faster than its peers. An accelerated growth means accelerated share-price appreciation, all else equal. This growth potential can be especially rewarding in the world of small-cap stocks. While the risks are higher — a smaller company can grow faster but it can also falter easier as it often lacks the kind of resources needed to break through competition barriers — the rewards can be significant. This is why over at Game-Changing Stocks, we continue to emphasize growth companies. And this is why the stock screen I want to share with you today is about growth as well. The Screen: Small-Cap Growth Stocks I searched for companies with market capitalization of $1 billion… Read More

I recently finished remaking one of the rooms at my house into a personal office. After rearranging and unpacking boxes, I found myself thumbing through an old copy of “Beating the Street,” by Peter Lynch. It had been a while since I’ve read it, and I can faithfully report that most of what Lynch writes about still holds up in today’s market. I’m sure you’re familiar with Lynch, but his track record bears repeating. While at the helm of the Magellan Fund at Fidelity, Lynch delivered a 29.2% average annual return from 1977 to 1990. Probably the greatest mutual fund… Read More

I recently finished remaking one of the rooms at my house into a personal office. After rearranging and unpacking boxes, I found myself thumbing through an old copy of “Beating the Street,” by Peter Lynch. It had been a while since I’ve read it, and I can faithfully report that most of what Lynch writes about still holds up in today’s market. I’m sure you’re familiar with Lynch, but his track record bears repeating. While at the helm of the Magellan Fund at Fidelity, Lynch delivered a 29.2% average annual return from 1977 to 1990. Probably the greatest mutual fund manager of all time, we have Lynch to thank for popular investing phrases like “invest in what you know,” “10-bagger” (a stock that gains 1,000%), “GARP” (growth at a reasonable price), and more. But what you might not know about Lynch is the story behind his exit from the Magellan Fund… —Recommended Link— The Single Best Group of Stocks to Buy NOW Since 1926, one collection of stocks has accounted for HALF of the S&P’s return — through every market environment imaginable. If you don’t have these picks in your own portfolio, you could be missing out on the… Read More

Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits… Read More

Over at Fast-Track Millionaire, our mandate requires us to stay abreast of the most recent scientific achievements.  And how could it be any other way? Most game-changing companies change the game by either finding real-life applications for modern scientific or technological discoveries or using those discoveries to modernize or disrupt entire businesses or industries.  We’ve had good success with these types of investments so far — but they don’t come close to the kind of potential I’m seeing in one field in particular…  I’m talking about the up-and-coming field of personalized medicine. —Recommended Link— Congratulations On 10 Years Of Profits We’ve unleashed it again — our annual Game-Changing Predictions report, filled cover-to-cover with a dozen potentially life-changing picks for 2019. And to mark this 10th anniversary edition, we’re doing something a little different… In addition to the full write up on each prediction (complete with the tickers), the first 250 readers to claim their copy will get instant access to 2 additional “bonus picks” that are positioned to bring home double… even triple-digit gains in 2019. If the thought of an extra $1,543… $2,184… even $4,200 each month in cash sounds good to you, click here now to see if… Read More

It’s one of the few holdings in my Daily Paycheck portfolio that has lost ground in 2019… But there’s a good reason. On January 3, Bristol Myers Squibb (NYSE: BMY) unveiled plans to buy Celgene (Nasdaq: CELG) in a blockbuster $74 billion transaction.  Acquirers typically fall when these mega-deals are announced, while shares of the target bolt higher. True to form, BMY slid 14% on the news, while CELG jumped 25%.  Despite the drop, my subscribers and I are still in the black on this one. But is this a good deal? And is BMY worth owning today?  First, let’s… Read More

It’s one of the few holdings in my Daily Paycheck portfolio that has lost ground in 2019… But there’s a good reason. On January 3, Bristol Myers Squibb (NYSE: BMY) unveiled plans to buy Celgene (Nasdaq: CELG) in a blockbuster $74 billion transaction.  Acquirers typically fall when these mega-deals are announced, while shares of the target bolt higher. True to form, BMY slid 14% on the news, while CELG jumped 25%.  Despite the drop, my subscribers and I are still in the black on this one. But is this a good deal? And is BMY worth owning today?  First, let’s get some of the specifics out of the way. Bristol Myers is offering one share of BMY and $50 cash for each share of CELG. There is also the possibility of additional cash remuneration for Celgene investors later down the line (known as a contingent value right, or CVR) if three drugs in the firm’s pipeline eventually gain regulatory approval.  Based on BMY’s share price at the time of the announcement, the bid (excluding CVRs) works out to a little more than $102 per share. That’s a healthy premium of 53% above where CELG closed the day before the announcement. … Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size… Read More

It’s only been a little over three months since marijuana became legal in Canada, but the country’s government statistics agency has already added a relevant report to its monthly data set. Statistics Canada, the national statistical office, now reports revenues generated by cannabis as part of its standard monthly retail sales report. And thanks to that addition, we learned on Jan. 23 that Canadians bought $41 million (U.S. dollars) of marijuana from retail stores in November, the first full month since the legalization became a fact of life. If anything, this number is an understatement of the true market size for legal pot in Canada. Retail stores are still opening; Ontario, the country’s largest state, still hasn’t opened any retail stores (in this state, sales are still limited to online orders). Further, the demand was so strong that a number of stores ran out of product. Canopy Growth: Best In The Business In the three months since I first added Canada’s Canopy Growth Corp. (NYSE: CGC) to the our Fast-Track Millionaire portfolio, the stock has handily outperformed its closest peer, Tilray (Nasdaq: TLRY). While TILR has lost nearly 30% of its value over these three months, CGC has appreciated by more… Read More

Since December 24, when the S&P 500 registered its lowest mark of 2018 (and a near 20% pullback from its September highs) we’ve seen a robust rebound. The index has rallied more than 12% since then.  I don’t know whether we’re out of the woods just yet… but between a couple of bullish indicators that I’ll discuss below, and my Maximum Profit system signaling four new buys last week, I’d say that the outlook at the moment is positive.  —Recommended Link— What would YOU do with an extra $3,080 every month for the rest of your life? Never worry… Read More

Since December 24, when the S&P 500 registered its lowest mark of 2018 (and a near 20% pullback from its September highs) we’ve seen a robust rebound. The index has rallied more than 12% since then.  I don’t know whether we’re out of the woods just yet… but between a couple of bullish indicators that I’ll discuss below, and my Maximum Profit system signaling four new buys last week, I’d say that the outlook at the moment is positive.  —Recommended Link— What would YOU do with an extra $3,080 every month for the rest of your life? Never worry about cash again. Be free to live how YOU want… go on a lavish vacation… or build up a college fund for the grandkids–it’s up to you.  Get your share here… Indicator #1 The first bullish indicator is one that I touched on previously, and that’s the Advance-Decline Line (AD Line). This is a breadth indicator that shows us how many stocks in the underlying index — the NYSE Composite Index in this case — are advancing and how many are declining. The purpose of looking at a breadth indicator is to gauge market sentiment, whether it’s leaning… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match… Read More

It’s been hard not to notice how slow this year has been when it comes to bringing new companies to the market via initial public offerings (IPOs).  Last quarter’s market selloff plus government shutdown-related staffing issues at regulatory agencies such as the Securities and Exchange Commission are largely to blame. As of last Friday, Jan. 18, only three companies had gone public so far this year, with another expected to make its debut on Jan. 25. In January 2018, by contrast, 20 companies had IPO-ed. This pace puts the IPO market of 2019 well behind the rate needed to match or exceed the breakneck activity of 2018 when 190 companies went public.  But this does not mean we cannot learn or benefit from the IPO market — these 190 recently-minted public companies offer a lot of new ideas and fresh profit opportunities.  Because of the sheer number of these fledgling companies, I had to first narrow down my area of interest. At this time, I’m focusing on the consumer discretionary sector. With numerous innovations hitting the consumer market, I thought it would be interesting to see how well these companies are being received by the investing public.  Hence, today’s… Read More